Market Research Report
Chikungunya Fever - Pipeline Review, H2 2019
|Published by||Global Markets Direct||Product code||251540|
|Published||Content info||122 Pages
Delivery time: 1-2 business days
|Chikungunya Fever - Pipeline Review, H2 2019|
|Published: December 16, 2019||Content info: 122 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever - Pipeline Review, H2 2019, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape.
Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting and rash and fever. Treatment includes use of NSAIDs.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chikungunya Fever - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chikungunya Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 7, 22 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 6 and 2 molecules, respectively.
Chikungunya Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.